IL176737A0 - Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases - Google Patents
Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseasesInfo
- Publication number
- IL176737A0 IL176737A0 IL176737A IL17673706A IL176737A0 IL 176737 A0 IL176737 A0 IL 176737A0 IL 176737 A IL176737 A IL 176737A IL 17673706 A IL17673706 A IL 17673706A IL 176737 A0 IL176737 A0 IL 176737A0
- Authority
- IL
- Israel
- Prior art keywords
- pyrazolo
- pyrimidin
- treatment
- protein kinase
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53822004P | 2004-01-22 | 2004-01-22 | |
PCT/EP2005/000602 WO2005070431A1 (en) | 2004-01-22 | 2005-01-21 | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL176737A0 true IL176737A0 (en) | 2006-10-31 |
Family
ID=34807167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL176737A IL176737A0 (en) | 2004-01-22 | 2006-07-06 | Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1708710A1 (en) |
JP (1) | JP2007519662A (en) |
KR (1) | KR20070009546A (en) |
CN (1) | CN1909908A (en) |
AR (1) | AR049769A1 (en) |
AU (1) | AU2005205915B2 (en) |
BR (1) | BRPI0507071A (en) |
CA (1) | CA2552885A1 (en) |
EC (1) | ECSP066718A (en) |
IL (1) | IL176737A0 (en) |
MA (1) | MA28400B1 (en) |
NO (1) | NO20063758L (en) |
PE (1) | PE20051089A1 (en) |
RU (1) | RU2006130003A (en) |
TN (1) | TNSN06226A1 (en) |
TW (1) | TW200528103A (en) |
WO (1) | WO2005070431A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
ATE533770T1 (en) | 2005-10-06 | 2011-12-15 | Schering Corp | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS |
EP1942900B1 (en) * | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases |
ES2761180T3 (en) | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Bicyclic heteroaryl compounds |
AU2007223865A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
GB0606804D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic Compounds |
GB0606805D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
CA2664375A1 (en) * | 2006-09-28 | 2008-04-03 | Novartis Ag | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
US20120029204A1 (en) * | 2007-06-07 | 2012-02-02 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
US8591943B2 (en) | 2009-04-09 | 2013-11-26 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors |
CA2774769A1 (en) | 2009-09-30 | 2011-04-07 | Schering Corporation | Novel compounds that are erk inhibitors |
UY33227A (en) * | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
MX365251B (en) | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Macrocyclic compounds as trk kinase inhibitors. |
RU2562833C2 (en) * | 2010-08-09 | 2015-09-10 | НБ Хелс Лаборатори Ко. Лтд. | Inhibitor of casein kinase 1 delta and casein kinase 1 ? |
WO2012023143A1 (en) | 2010-08-19 | 2012-02-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
US20150038500A1 (en) * | 2011-11-25 | 2015-02-05 | Catholic University Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing and treating ophthalmic disorders |
CN105906630B (en) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor |
PL3322706T3 (en) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CN106588893A (en) * | 2016-12-01 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | Preparation of vilazodone double oxide |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI802635B (en) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
TW201932464A (en) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolyl[4,3-C]pyridine compounds as RET kinase inhibitors |
EP3746075A4 (en) * | 2018-01-29 | 2021-09-08 | Merck Patent GmbH | Gcn2 inhibitors and uses thereof |
ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
CN109836428A (en) * | 2019-02-27 | 2019-06-04 | 华东师范大学 | Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity |
WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
IL293191A (en) | 2019-11-25 | 2022-07-01 | Amgen Inc | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
WO2023154282A1 (en) * | 2022-02-08 | 2023-08-17 | Theras, Inc. | Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications |
CN114751910B (en) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | Compound capable of inducing cell megalophage death and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3130633A1 (en) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM |
DE69130683T2 (en) * | 1991-04-22 | 1999-05-06 | Otsuka Pharma Co Ltd | PYRAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AND ANTI-INFLAMMATORY CONTAINERS THEREOF |
US5707997A (en) * | 1994-06-21 | 1998-01-13 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo 1,5-a!pyrimidine derivative |
JP3163413B2 (en) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | Painkillers |
WO1998010590A1 (en) * | 1996-09-02 | 1998-03-12 | Sony Corporation | Device and method for transmitting video signal |
KR20050057139A (en) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
EP1545533A1 (en) * | 2002-09-04 | 2005-06-29 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
-
2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/en not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/en unknown
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/en not_active IP Right Cessation
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/en active Pending
- 2005-01-21 TW TW094101852A patent/TW200528103A/en unknown
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/en active Pending
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/en not_active Application Discontinuation
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en active Application Filing
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/en not_active Application Discontinuation
-
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/en unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/en unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2552885A1 (en) | 2005-08-04 |
TW200528103A (en) | 2005-09-01 |
AR049769A1 (en) | 2006-09-06 |
BRPI0507071A (en) | 2007-06-19 |
TNSN06226A1 (en) | 2007-12-03 |
MA28400B1 (en) | 2007-01-02 |
WO2005070431A1 (en) | 2005-08-04 |
AU2005205915B2 (en) | 2009-05-21 |
JP2007519662A (en) | 2007-07-19 |
EP1708710A1 (en) | 2006-10-11 |
CN1909908A (en) | 2007-02-07 |
RU2006130003A (en) | 2008-04-10 |
NO20063758L (en) | 2006-10-23 |
KR20070009546A (en) | 2007-01-18 |
PE20051089A1 (en) | 2006-01-25 |
AU2005205915A1 (en) | 2005-08-04 |
ECSP066718A (en) | 2006-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL176737A0 (en) | Pyrazolo[1,5-a] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
ZA200802998B (en) | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases | |
HK1085740A1 (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2- a] pyrimidin-6-one derivatives and their use against neurogenerative diseases | |
HK1134486A1 (en) | 4, 5-dihydro- [1, 2, 4] triazolo [4,3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders plk1 45--[124][43- f] | |
IL183110A0 (en) | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof | |
EP1945222A4 (en) | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | |
ZA200704476B (en) | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases | |
IL190510A (en) | Derivatives of pyrazolo[1,5-a]pyrimidin-7-ylamine substituted by halogen in position 6 and by (1- or 2-)methylpyrazol-4-yl in position 3, and pharmaceutical compositions comprising same | |
NO20053955D0 (en) | Pyrazolo [1,5-A] pyrimidine derivatives | |
EP1796467A4 (en) | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | |
IL201977A (en) | 6-(pyrrolidin-3-yl)-pyrazolo[3,4-d]pyrimidin-4-ones, pharmaceutical compositions comprising them and their use in the preparation of medicaments for the treatment of diseases | |
IL180757A0 (en) | Imidazo[4,5-d] pyrimidines, their uses and methods of preparation | |
IL219669A0 (en) | PYRAZOLO [1,5-a]PYRIDINES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT | |
HK1110859A1 (en) | Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy | |
MX2009002995A (en) | Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use. | |
IL179736A (en) | 5 - PHENYL - PYRAZOLO [1,5-a] PYRIMIDINE - 3 - CARBOXYLIC ACID (3 - SULFONYL - PHENYL) - AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF ACUTE OR CHRONIC NEUROLOGICAL DISORDERS | |
PL377227A1 (en) | Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments | |
WO2006017822A3 (en) | Quinazoline derivatives and their use in the treatment of thrombocythemia | |
PT2020410E (en) | Pyrido[2,3-d]pyrimidine derivatives, process for their preparation and their therapeutical use | |
IL175753A0 (en) | PROCESSES FOR THE PREPARATION OF PYRAZOLO [1,5-a]-1,3,5-TRIAZINES AND INTERMEDIATES THEREOF | |
IL183485A0 (en) | Therapeutic pyrazolo[3,4-b] pyridines and indazoles | |
AP2005003362A0 (en) | Formulation and methods for the treatment of thrombocythemia. | |
MY136822A (en) | Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins | |
ZA200809016B (en) | 4, 5-Dihydro-[1,2,4] Triazolo [4,3-F] PteridinesS as protein kinase PLK1 inhibitors for the treatment of proliferative disorders | |
WO2007027233A3 (en) | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid |